HemOnc Today New York
HemOnc Today New York
April 15, 2019
2 min watch

VIDEO: Management of locally advanced head and neck cancer continues to evolve

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — Joshua Bauml, MD, assistant professor of medicine in the division of hematology/oncology at Perelman School of Medicine at University of Pennsylvania, spoke at HemOnc Today New York about management of locally advanced head and neck cancer.

“This is a field that is changing right around us,” Bauml told HemOnc Today. “We’re now seeing that p16-positive and p16-negative cancers are completely different, and their management needs to be focused on what type of cancer you are treating.”

Bauml’s talk focused on the choice between cisplatin or cetuximab (Erbitux, Eli Lilly) — administered with concurrent radiation — and the role HPV status may play in that decision. Bauml also addressed the approach he follows for patients who are not ideal candidates for cisplatin.


Disclosure: Bauml reports research/grant support from AstraZeneca, Bayer, Carevive Systems, Clovis, Janssen, Merck, Novartis and Takeda, as well as consultant services to AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Clovis, Genentech, Guardant Health, Janssen, Merck and Takeda.